Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE) Meeting Abstract
| Authors: | Patel, J. N.; Jiang, C.; Hertz, D. L.; Mulkey, F.; Friedman, P. N.; Halabi, S.; Ratain, M. J.; Morris, M. J.; Small, E. J.; Owzar, K.; Kelly, W. K.; McLeod, H. L. |
| Abstract Title: | Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613200815 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.e16061 |
| Notes: | Meeting Abstract: e16061 -- Source: Wos |
